Enhancing Cell And Gene Therapy: The LVV Platform Advantage

By Barbara Paugh and Joanna Manoranjan, Miltenyi Bioindustry

Many drug development platforms focus solely on cost reduction or improved process efficiency, offering few, if any, solutions to bolster biological performance. Miltenyi’s lentiviral vector (LVV) platform is specifically designed to achieve both, generating consistent, high-quality vectors without sacrificing timeline and cost benefits.

The platform production process also institutes a step-by-step structure for molecular biology feasibility and review to ensure nothing is overlooked, and each client project benefits from a holistic assessment to ensure an understanding of their gene sequences and stated needs, as well as opportunities for sequence optimization.

Optimization evaluation looks at the type of promoters, the transgene sequence, regulatory elements, and how the interaction between these elements impacts product performance. Improving titer, transgene expression, and/or sequence integrity are typical optimization goals. Sequence complexity increases as payloads and the number of genes clients wish to include in their constructs increases, so optimization often addresses challenges associated with that complexity.